M. Hanafiah, K. Groeger, J. Flaxman, A. D. Wiersma, and S. T. , Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence, Hepatology, vol.57, issue.4, pp.1333-1375, 2013.

G. Mortality and C. , Causes of death. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study, Lancet, vol.385, issue.9963, pp.117-71, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01285506

E. Gower, C. Estes, S. Blach, K. Razavi-shearer, and H. Razavi, Global epidemiology and genotype distribution of the hepatitis C virus infection, J Hepatol, vol.61, issue.1, pp.45-57, 2014.

, Towards the elimination of hepatitis B and C by 2030, 2016.

, Draft global health sector strategy on viral hepatitis, 2016.

M. Lemoine and M. Thursz, Viral hepatitis: scaling up HCV treatment in resource-limited countries, Nat Rev Gastroenterol Hepatol, vol.12, issue.4, pp.193-94, 2015.

S. Chevaliez, A. Soulier, L. Poiteau, M. Bouvier-alias, and J. Pawlotsky, Clinical utility of hepatitis C virus core antigen quantification in patients with chronic hepatitis C, J Clin Virol, vol.61, issue.1, pp.145-193, 2014.

J. R. Ticehurst, F. M. Hamzeh, and D. L. Thomas, Factors affecting serum concentrations of hepatitis C virus (HCV) RNA in HCV genotype 1-infected patients with chronic hepatitis, J Clin Microbiol, vol.45, issue.8, pp.2426-2459, 2007.

J. A. Morrill, M. Shrestha, and R. W. Grant, Barriers to the treatment of hepatitis C. Patient, provider, and system factors, J Gen Intern Med, vol.20, issue.8, pp.754-58, 2005.

J. T. Coats and J. F. Dillon, The effect of introducing point-of-care or dried blood spot analysis on the uptake of hepatitis C virus testing in high-risk populations: a systematic review of the literature, Int J Drug Policy, vol.26, issue.11, pp.1050-55, 2015.

, UNODC. World drug report, 2015.

A. L. Bowring, N. Luhmann, S. Pont, C. Debaulieu, S. Derozier et al., An urgent need to scale-up injecting drug harm reduction services in Tanzania: prevalence of blood-borne viruses among drug users in Temeke District, Int J Drug Policy, vol.24, issue.1, pp.78-81, 2011.

T. Muasya, W. Lore, K. Yano, H. Yatsuhashi, F. R. Owiti et al., Prevalence of hepatitis C virus and its genotypes among a cohort of drug users in Kenya, East Afr Med J, vol.85, issue.7, pp.318-343, 2008.

L. Duchesne, R. Njouom, F. Lissock, G. F. Tamko-mella, S. Rallier et al., HCV Ag quantification as a one-step procedure in diagnosing chronic hepatitis C infection in Cameroon: the ANRS 12336 study, J Int AIDS Soc, vol.20, issue.1, pp.1-8, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01536669

Z. Mohamed, Journal of the International AIDS Society, vol.20, 2017.

J. Bronowicki, D. Ouzan, T. Asselah, H. Desmorat, J. Zarski et al., Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin, Gastroenterology, vol.131, issue.4, pp.1040-1088, 2006.

A. Lepretre, I. Ba, K. Lacombe, M. Maynart, A. Toufik et al., Prevalence and behavioural risks for HIV and HCV infections in a population of drug users of Dakar, Senegal: the ANRS 12243 UDSEN study, J Int AIDS Soc, vol.18, 2015.

A. , Seroprevalence of HIV, HBC and HCV in injecting drug users in Nairobi, Kenya: World Health Organization drug injecting study Phase II findings. 15th International AIDS Conference, 2004.

V. B. Rao, N. Johari, D. Cros, P. Messina, J. Ford et al., Hepatitis C seroprevalence and HIV co-infection in sub-Saharan Africa: a systematic review and meta-analysis, Lancet Infect Dis, vol.15, issue.7, pp.819-843, 2015.

J. M. Freiman, T. M. Tran, S. G. Schumacher, L. F. White, S. Ongarello et al., Hepatitis C core antigen testing for diagnosis of hepatitis C virus infection: a systematic review and meta-analysis, Ann Intern Med, vol.165, issue.5, pp.345-55, 2016.

A. Soulier, L. Poiteau, I. Rosa, C. Hézode, F. Roudot-thoraval et al., Dried blood spots: a tool to ensure broad access to hepatitis C screening, diagnosis, and treatment monitoring, J Infect Dis, vol.213, issue.7, pp.1087-95, 2016.

M. Van-tilborg, G. Cherepanov, A. Aquino, T. Mazulli, M. Kowgier et al., Can dried blood spots be used for diagnosis of chronic hepatitis C infection, even when they are stored under non-ideal conditions?, 2017.

T. Roberts, H. Simplified, and . Diagnostics, WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection, INHSU. 2016. 24. Thursz M, Lacombe K, vol.213, pp.1055-56, 2013.

D. Kania, A. M. Bekalé, N. Nagot, A. Mondain, L. Ottomani et al., Combining rapid diagnostic tests and dried blood spot assays for point-of-care testing of human immunodeficiency virus, hepatitis B and hepatitis C infections in, Clin Microbiol Infect, vol.19, issue.12, pp.533-574, 2013.

S. Chevaliez, J. Feld, K. Cheng, H. Wedemeyer, C. Sarrazin et al., Clinical utility of HCV core antigen detection and quantification in the diagnosis and management of patients with chronic hepatitis C receiving an all-oral, interferon-free regimen, J Clin Virol, vol.46, issue.3, pp.210-225, 2009.

Z. Mohamed, Journal of the International AIDS Society, vol.20, 2017.